SGLT2 Inhibition Updates 2021 - SGLT2 Inhibition in Cardiorenal Disease
Published: 20 July 2021
-
Views:
25033
-
Likes:
7
-
Views:
25033
-
Likes:
7
-
Up Next -
6m 58sPart 2 | Session 4 Panel Discussion
-
3m 56sPart 3 | Session 1 Totality of Evidence for the Cardiorenal Patient -
50m 42sPart 3 | Session 2 Discussion
-
1m 55sPart 4 | Session 1 Welcome and Introduction -
43mPart 4 | Session 2 KCCQ Score Overview and Discussion
-
1m 11sPart 5 | Session 1 Welcome and Introduction -
7m 5sPart 5 | Session 2 SGLT2i in the Elderly and Vulnerable Patients -
27m 15sPart 5 | Session 3 Discussion
-
1m 20sPart 6 | Session 1 Welcome and Introduction -
11m 2sPart 6 | Session 2 How do SGLT2 Inhibitors Bring About Cardiorenal Benefits? -
11m 24sPart 6 | Session 3 Totality of Evidence in Heart Failure -
11m 20sPart 6 | Session 4 Trial Results Coming Out Soon -
10m 55sPart 6 | Session 5 Heart Failure Guidelines -
14m 37sPart 6 | Session 6 Panel Discussion
-
1m 1sPart 7 | Session 1 Welcome and Introduction -
17m 18s -
11m 29sPart 7 | Session 3 Panel Discussion
-
11m 8sPart 8 | Session 1 Welcome and Introduction -
6m 43sPart 8 | Session 2 Soloist Trial Overview -
36m 32sPart 8 | Session 3 Discussion
-
50m 20s
-
25m 59s
-
53sPart 1 | Session 1 Welcome and Introduction Stefan Anker, Shelley Zieroth
-
10m 23sPart 1 | Session 2 SGLT2 Inhibitors for Patients with Diabetes and an Increased CV Risk: How The Success Story Started Bernard Zinman
-
9m 18sPart 1 | Session 3 SGLT2 Inhibitors: Evolution from Glucose Lowering to Cardiorenal Protection Milton Packer
-
12m 18sPart 1 | Session 4 SGLT2 Inhibitors in Cardiology Indications: The Data John JV McMurray
-
9m 38sPart 1 | Session 5 SGLT2 Inhibitors in Chronic Kidney Disease: The Data Katherine Tuttle
-
14m 38sPart 1 | Session 6 Panel Discussion Stefan Anker, Shelley Zieroth, Andrew JS Coats, Bernard Zinman, John JV McMurray, Katherine Tuttle
-
9m 39sPart 2 | Session 1 Place of SGLT2 Inhibitors in the Heart Failure Treatment Algorithm Andrew JS Coats
-
8m 1sPart 2 | Session 2 SGLT2 Inhibitors: Safety Considerations Gerasimos Filippatos
Overview
Organised with scientific co-chairs Stefan Anker and Andrew Coats, this event includes presentations and panel discussions with a host of international thought-leaders.
The SGLT2 Updates 2021 conference SGLT2 Inhibition in Cardiorenal Disease: Translating Evidence into Clinical Practice covers the place of SGLT2 inhibitors in the newly released guidelines of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) as well as their implementation in clinical practice.
In addition to plenary sessions and satellite symposia the conference featured a number of Meet The Expert breakout sessions discussing the implications in treatment of specific patient subgroups including patients with comorbidities. Audience questions were submitted throughout and were addressed by the panel experts.
Educational Objectives
SGLT2 Inhibition in Cardiorenal Disease
- Prepare cardiologists, nephrologists and endocrinologists to effectively manage patients with heart failure, individually and collaboratively
- Apply findings from clinical trials into clinical practice
- Describe the role of SGLT2 inhibitors in different patient subgroups, including patients with comorbidities
- Evaluate the safety and cardiorenal benefits of glucose-lowering agents
- Implement the new guidelines of the HFA of the ESC in clinical practice
Target Audience
- Cardiologists
- Nephrologists
- Endocrinologists
More from this programme
Part 1
State of the Art 1
Part 2
SGLT2 Inhibitors in Heart Failure: A Practical Approach
Part 3
Meet The Expert: Implications for Clinical Practice - Breakout 1
Part 4
Meet The Expert: Implications for Clinical Practice - Breakout 2
Part 5
Meet The Expert: Implications for Clinical Practice - Breakout 3
Part 6
State of the Art 2
Part 7
SGLT2 Inhibitors for Heart Failure: The New Standard of Care
Part 8
Meet The Expert: Implications for Clinical Practice - Breakout 4
Part 9
Meet The Expert: Implications for Clinical Practice - Breakout 5
Part 10
Meet The Expert: Implications for Clinical Practice - Breakout 6
Faculty Biographies
Javed Butler
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.
He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.